Literature DB >> 9836077

Interpretation of bone mineral density values in pediatric Crohn's disease.

D Herzog1, N Bishop, F Glorieux, E G Seidman.   

Abstract

Patients with Crohn's disease (CD) often have low bone mineral density (BMD) for their chronological age (CA). However, pediatric cases frequently have growth failure and delayed bone age (BA) and height age (HA). Do they really have the amount of osteoporosis as measured by BMD and calculated for their CA? The aim was to compare z-scores for BMD in relation to CA and z-scores corrected for BA or height age in pediatric patients. A group of 43 pediatric patients (mean age, 12 years; 14 girls, 29 boys) with CD in remission, prospectively had BMD (measured by dual energy x-ray absorptiometry) and BA. Abnormally low z-score for BMD (below 2 standard deviation [SD] for CA was found in 19 patients (44%). Among these, 9 patients (21% overall) had a BA of more than 2 SD lower than their CA and 12 had height age at least 2 years below CA. When the BMD z-score in these patients was corrected for their BA and height age, 6 of 9 and 8 of 12 patients had a normal BMD. In conclusion, when corrected for BA or CA delay, BMD was abnormal in 26 to 30% rather than 44% of cases. Correct assessment of BMD in Crohn's disease patients with bone age delay requires interpretation in terms of BA or HA, rather than CA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9836077     DOI: 10.1002/ibd.3780040402

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

Review 1.  Inflammatory bowel disease.

Authors:  R M Beattie; N M Croft; J M Fell; N A Afzal; R B Heuschkel
Journal:  Arch Dis Child       Date:  2006-05       Impact factor: 3.791

Review 2.  Recent advances in the diagnosis and treatment of pediatric inflammatory bowel disease.

Authors:  E G Seidman
Journal:  Curr Gastroenterol Rep       Date:  2000-06

Review 3.  Neoplastic and other complications of inflammatory bowel disease.

Authors:  C N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2000-12

4.  Vitamin D status in children and young adults with inflammatory bowel disease.

Authors:  Helen M Pappa; Catherine M Gordon; Tracee M Saslowsky; Anna Zholudev; Brian Horr; Mei-Chiung Shih; Richard J Grand
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

Review 5.  Perspectives on osteoporosis in pediatric inflammatory bowel disease.

Authors:  Manisha Harpavat; David J Keljo
Journal:  Curr Gastroenterol Rep       Date:  2003-06

6.  Growth hormone treatment for growth failure in pediatric patients with Crohn's disease.

Authors:  Melvin B Heyman; Elizabeth A Garnett; Janet Wojcicki; Neera Gupta; Cheryl Davis; Stanley A Cohen; Benjamin D Gold; Barbara S Kirschner; Robert N Baldassano; George D Ferry; Harland S Winter; Selna Kaplan
Journal:  J Pediatr       Date:  2008-06-27       Impact factor: 4.406

Review 7.  Pathological fractures in paediatric patients with inflammatory bowel disease.

Authors:  Sze Choong Wong; A G Anthony Catto-Smith; Margaret Zacharin
Journal:  Eur J Pediatr       Date:  2013-10-17       Impact factor: 3.183

8.  Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease.

Authors:  Mostafa Abdel-Aziz El-Hodhod; Ahmad Mohamed Hamdy; Amal Ahmed Abbas; Sherine George Moftah; Alhag Ahmed Mohamed Ramadan
Journal:  BMC Gastroenterol       Date:  2012-05-02       Impact factor: 3.067

9.  Vitamin D Status and Bone Mineral Density in Children with Inflammatory Bowel Disease Compared to Those with Functional Abdominal Pain.

Authors:  Jenny Sohn; Eun Jae Chang; Hye Ran Yang
Journal:  J Korean Med Sci       Date:  2017-06       Impact factor: 2.153

10.  Age-of-onset-dependent influence of NOD2 gene variants on disease behaviour and treatment in Crohn's disease.

Authors:  Carsten Posovszky; Veronika Pfalzer; Georgia Lahr; Jan Hendrik Niess; Jochen Klaus; Benjamin Mayer; Klaus-Michael Debatin; Georg B T von Boyen
Journal:  BMC Gastroenterol       Date:  2013-05-02       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.